Biologicals targeting immunoglobulin E (IgE), such as omalizumab, or T helper (TH) 2 cell cytokines, including interleukin-4 (IL-4), IL-5 and IL-13, have been tested for different allergic disorders. Omalizumab has been shown to be effective in allergic asthma, allergic rhinitis, chronic urticaria, atopic dermatitis and as an adjunct treatment to specific immunotherapy. Many other biologicals are currently being assessed for their efficacy in certain allergic disease subsets.
Although biological agents are currently providing outstanding support in multiple immune-mediated diseases, a better understanding of their fine mechanisms of action, their long-term effects, and their adverse effects, will need the collaboration of a large network of clinicians and researchers working on immunology and allergy. Having recognized the importance of these above-mentioned issues on biologicals and with the endorsement of the Executive Committee of the EAACI, an Interest Group (IG) on Biologicals has been established within the EAACI in 2012.
This IG on Biologicals is fostering the following research and clinical subjects:
- To stimulate basic and clinical research in the area of biologicals, especially the ones used for the treatment of immune-mediated diseases and for immunotherapy.
- To facilitate the scientific exchange between networks of clinicians and researchers interested in this topic.
- To create a comprehensive database with conclusive and outstanding data on desired and adverse effects of biologicals.
- To formulate guidelines for future research and clinical trials on short, medium and long-term effects of biologicals.
New members are welcome and invited to join the interest group!
Last updated 24 October 2016